Lynch syndrome lesions, however, also possess immunosuppressive entities such as (a) alterations in MHC class I antigen presentation, (b) TGFβRII mutations, (c) upregulation of PD-L1 on tumor-associated T cells, and (d) tumor-associated FOXP3+ regulatory T cells. The gene discussed is CD274; the disease is neoplasm.